Dana-Farber Researchers Unveil Promising Phase 2 Results for Targeted Therapy in Rare Bile Duct Cancer
A Breakthrough in Targeted Therapy: Zenocutuzumab Offers Hope for Patients with Rare NRG1-Positive Cholangiocarcinoma Cholangiocarcinoma, a rare but aggressive malignancy ...
